GH Research PLC
GHRS
Company Profile
Business description
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Contact
Dawson Street
Joshua Dawson House
Dublin 2D02 RY95
IRLT: +353 14378334
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
50
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,434.50 | 34.70 | 0.41% |
| CAC 40 | 7,626.84 | 70.08 | -0.91% |
| DAX 40 | 23,115.96 | 133.69 | -0.58% |
| Dow JONES (US) | 41,113.97 | 284.97 | 0.70% |
| FTSE 100 | 8,559.33 | 38.09 | -0.44% |
| HKSE | 22,941.91 | 250.03 | 1.10% |
| NASDAQ | 17,738.16 | 48.50 | 0.27% |
| Nikkei 225 | 36,896.00 | 116.34 | 0.32% |
| NZX 50 Index | 12,526.06 | 29.17 | 0.23% |
| S&P 500 | 5,631.28 | 24.37 | 0.43% |
| S&P/ASX 200 | 8,205.20 | 26.90 | 0.33% |
| SSE Composite Index | 3,355.26 | 12.60 | 0.38% |